alexa Predictive Biomarkers to Anti-EGFR Inhibitors Treatment
ISSN: 2157-2518

Journal of Carcinogenesis & Mutagenesis
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Predictive Biomarkers to Anti-EGFR Inhibitors Treatment in the Management of Metastatic Colorectal Cancer

Teresa Troiani1*, Stefania Napolitano1, Floriana Morgillo1, Fortunato Ciardiello1, Giulio Belli2, Luigi Cioffi2, Cesare Sirignano3 and Erika Martinelli1
1Oncologia Medica, Dipartimento Medico-Chirurgico di Internistica Clinica e Sperimentale F. Magrassi e A. Lanzara, Seconda Università degli Studi di Napoli, Naples, Italy
2S. Maria Loreto Nuovo Hospital, General and Hepato-Pancreato-Biliary Surgery, Naples, Italy
3Istituto di Biostrutture e Bioimmagini (IBB)-Consiglio Nazionale delle Ricerche (CNR), Università degli Studi di Napoli, Naples, Italy
Corresponding Author : Teresa Troiani
Dipartimento Medico-Chirurgico di Internistica
Clinica e Sperimentale “F.MagrassieA.Lanzara”
Seconda z Università degli Studi di Napoli, Italy
Via S. Pansini 5, 80131, Naples, Italy
Tel: +390815666725
Fax: +390815666732
E-mail: [email protected]
Received January 23, 2014; Accepted February 19, 2014; Published February 25, 2014
Citation: Troiani T, Napolitano S, Morgillo F, Ciardiello F, Belli G et al. (2014) Predictive Biomarkers to Anti-EGFR Inhibitors Treatment in the Management of Metastatic Colorectal Cancer. J Carcinog & Mutagen S10:001. doi:10.4172/2157-2518.S10-001
Copyright: © 2014 Troiani T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Despite the epidermal growth factor receptor (EGFR) monoclonal antibodies (moAbs), cetuximab and panitumumab, have expanded the range of treatment options for metastatic colorectal cancer (mCRC), the prognosis of these patients remains poor. In fact, resistance mechanisms limit the effectiveness of current cancer therapies to treat mCRC. The identification of resistance mechanisms may highlight new biomarkers useful to predict the clinical outcome or the likely responsiveness to pharmacological treatment of those metastatic CRC patients who cannot benefit to anti-EGFR moAbs. Data derived from multiple clinical trials have clearly demonstrated that KRAS mutations can be considered specific negative biomarkers of response to anti-EGFR monoclonal antibodies. Other molecular aberrations in the downstream pathway of EGFR such as BRAF, NRAS, and PIK3CA mutations, and PTEN loss are useful for selecting patients with reduced chance to benefit from anti- EGFR moAbs. The recognition of panels of biomarkers may suggest new strategies to overcome resistance by rational drug design and combination treatment. In this review we discuss the most recent data on predictive and prognostic biomarkers within the EGFR pathway, the challenges this emerging field presents and the future role of these molecular markers in CRC treatment.


Share This Page

Additional Info

Loading Please wait..
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version